RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All TGA (Australia) updates
TGA (Australia)
SAFETY ALERT
Isotretinoin (Roaccutane)
Published: 4/6/2025Detected: 3/25/2026

Summary preview

Highlights safety considerations for isotretinoin related to mood-related changes and sexual disorders, reinforcing the need for robust risk communication and ongoing safety monitoring.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
dermatology
psychiatry
safety
#isotretinoin
#Roaccutane
#safety alert
#pharmacovigilance
#psychiatric disorders

Official Source Document
Source Verified

Access the original document directly from TGA.

View Official Document

More from TGA (Australia)

  • TGA issues infringement notices to 3 health practitioners for alleged unlawful importation of therapeutic goods3/25/2026
  • Improving the regulation of sunscreens in Australia3/25/2026
  • Counterfeit weight loss products claiming to contain GLP-13/1/2026
  • Natures Valley Collagen Builder tablets2/15/2026
  • Vape enforcement crackdown with major seizure in Burwood NSW2/9/2026

Get TGA (Australia) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.